IL10 and type 1 diabetes mellitus: Previous reports in the NOD model of diabetes have shown that the administration of the probiotic formulation VSL3 decreased the incidence of T1D through IL10 immunomodulation [30] and induction of pro-inflammatory cytokine IFNγ.